AllSci News
China's CDE launches PIONEER Program to advance NAMs in drug development
Category: Science & Innovation Policy | Regulatory Body: CDE (Center for Drug Evaluation, NMPA) | Geography: China | Instrument: Initiative launch
Cyllene Therapeutics secures EUR 33m Series C to advance HSV-based genetic medicine platform
France-based Cyllene Therapeutics, formerly known as EG 427, has closed a EUR 33 million Series C financing round to advance clinical development of EG110A,...
Vertex bets USD 10b on endocrinology diversification with Crinetics acquisition
Vertex Pharmaceuticals has agreed to acquire San Diego-based Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) for USD 85.00 per share in cash, representing a...
Agenus posts three-year survival data for botensilimab in MSS colorectal cancer
Agenus Inc. (Nasdaq: AGEN) reported three-year overall survival data from its Phase Ib C-800-01 trial at ESMO GI 2026 in Munich, showing that 33% of...
Incyte completes USD 2b Vega acquisition for VWD antibody
Incyte (Nasdaq: INCY) has completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of San Francisco-based Star Therapeutics LLC,...
OS Therapies seeks FDA alignment on survival endpoint for osteosarcoma gene therapy
OS Therapies, Inc. (NYSE American: OSTX) has requested a Type B meeting with the US FDA to resolve a central unresolved question…
Multitude presents early clinical validation for CDH17 ADC in colorectal cancer
Interim Phase I data from China-based Multitude Therapeutics reported a 20% overall response rate and a 91% disease control rate for AMT-676, a...
HutchMed’s Orpathys becomes first MET inhibitor approved for gastric cancer in China
HutchMed (China) Limited (Nasdaq: HCM) has received conditional NMPA approval for Orpathys (savolitinib) as the first selective MET inhibitor indicated for locally…
Brii Bio's HBV combo strategy validated, but Vir dispute clouds Phase III path
Brii Biosciences Limited reported end-of-treatment data from two Phase IIb studies that clarify the optimal combination strategy for BRII-179 in chronic HBV...
FDA halts Ascelia’s Orviglance approval, demands additional clinical data
Sweden-based Ascelia Pharma AB (STO: ACE) disclosed on July 3, 2026 that the US FDA issued a Complete Response Letter (CRL) for…
Otsuka's Astex strikes USD 515m breast cancer deal with Genentech on FBDD platform
Genentech has entered an exclusive worldwide research collaboration and license agreement with UK-based Astex Pharmaceuticals, paying USD 25 million upfront...
Junshi Bio hands Fosun Wanbang China commercial rights to roconkibart
China-based biopharma Shanghai Junshi Biosciences Co., Ltd. (HKEX: 01877) has granted Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. exclusive development, registration, and…
Scribe Therapeutics files for Nasdaq IPO with clinical-stage cardiovascular CRISPR pipeline
Scribe Therapeutics Inc. (Nasdaq: SCTX), a clinical-stage gene editing company co-founded by Nobel Laureate Dr. Jennifer Doudna and backed by more than USD...
Arcturus secures Thermo Fisher to manufacture inhaled mRNA therapy for Phase III cystic fibrosis trial
San Diego-based Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) and Thermo Fisher Scientific announced a strategic manufacturing and clinical research collaboration to support…
Sanyou Bio pairs with Baiyunshan for AI-powered radiopharmaceutical pipeline
China-based Sanyou Biopharmaceutical Co., Ltd. (Sanyou Bio) and Guangzhou Baiyunshan Xihe Health Pharmaceutical Co., Ltd. (Baiyunshan Xihe) announced a strategic collaboration covering…
The AllSci Brief
Free, systematic R&D and deal news. Daily.